Skip to main
TNYA
TNYA logo

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc is demonstrating promising advancements in its product candidates, particularly TN-201 and TN-401, with increased projected chances of success now at 30% and 15%, respectively. The encouraging results in left ventricular mass index (LVMI) and left ventricular posterior wall thickness (LVPWT) improvements, along with significant biomarker enhancements and stable safety profiles, suggest a viable pathway for accelerated approval in the gene therapy sector. Additionally, consistent positive outcomes in patient classifications and protein level increases bolster the company's potential for delivering innovative treatments for heart disease, enhancing the overall bullish sentiment regarding its future market prospects.

Bears say

Tenaya Therapeutics Inc faces significant risks related to potential delays in transitioning its preclinical assets to clinical trials, which could adversely affect market sentiment and lead to downward revisions of financial forecasts. Safety concerns, particularly regarding immune reactions, pose additional threats that could negatively influence investor confidence and the company's growth projections. Furthermore, the company's ability to develop adequate manufacturing capacity is critical; failures in this area could further constrain revenue forecasts and impact overall financial performance.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.